By IDSE News Staff
The FDA approved a new hexavalent vaccine (Vaxelis, Sanofi/Merck) indicated for active immunization to prevent diphtheria, tetanus, pertussis, inactivated poliovirus, hepatitis B virus (HBV) and invasive disease due to Haemophilus influenzae type b (DTPa-IPV-HepB-Hib). The vaccine is approved for use as a three-dose series in children aged 6 weeks through 4 years, prior to 5 years of age.
The vaccine contains diphtheria and tetanus toxoids, acellular pertussis adsorbed,